Meeting
2013 ASCO Annual Meeting
Gain of ALK gene copy number to predict lack of response to anti-EGFR treatment in advanced chemorefractory colorectal cancer (CRC) with KRAS/NRAS/BRAF/PI3KCA wild-type status.
Authors
Filippo Pietrantonio
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Filippo Pietrantonio , Anna Tessari , Rosalba Miceli , Pamela Biondani , Federica Perrone , Adele Testi , Elena Tamborini , Giuseppe Pelosi , Luigi Mariani , Giuseppe Fanetti , Arpine Gevorgyan , Ilaria Bossi , Maria Di Bartolomeo , Filippo G. De Braud
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Citation
J Clin Oncol 31, 2013 (suppl; abstr 3641)
DOI
10.1200/jco.2013.31.15_suppl.3641
Abstract #
3641
Poster Bd #
14C
Abstract Disclosures
Similar Posters
Poster
2015 Gastrointestinal Cancers Symposium
Clinical and molecular characterization of refractory BRAF mutant metastatic colorectal carcinoma (mCRC): Vall d’Hebron Institute of Oncology phase I program cohort.
First Author: Enrique Sanz-Garcia
Poster
2014 Gastrointestinal Cancers Symposium
Prevalence of KRAS, BRAF, NRAS, PIK3CA, and PTEN alterations in colorectal cancer: Analysis of a large international cohort of 5,900 patients.
First Author: Gargi Dan Basu
Poster
2024 ASCO Gastrointestinal Cancers Symposium
APC as a high-utility mutational biomarker that may identify subpopulations of patients with mutant RAS/BRAF and right-sided colorectal cancer (CRC) who derive benefit from EGFR inhibitors (EGFRi).
First Author: Ramya Thota
Poster
2024 ASCO Gastrointestinal Cancers Symposium
High-resolution transcriptional signature to predict survival benefit in colorectal cancer (CRC) treated with EGFR inhibitors (EGFRi) independent of RAS/BRAF mutation status or tumor sidedness.
First Author: Ramya Thota